| Ewaen Osamuyi Okao, MD, | |
|
13 N Hartford Ave, Atlanticare Behavioral Health, Atlantic City, NJ 08401-3512 | |
| (609) 348-1161 | |
| Not Available |
| Full Name | Ewaen Osamuyi Okao |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 29 Years |
| Location | 13 N Hartford Ave, Atlantic City, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528358652 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Recently, a research team led by Dr. DU Xuemin at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences created a new shape-morphing scaffold, enabling programmed deformation from a 2D planar cell-laden structure to a well-defined 3D tubular shape, which facilitated the facile 3D endothelialization of small-diameter vascular grafts.
› Verified 9 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Recently, a research team led by Dr. DU Xuemin at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences created a new shape-morphing scaffold, enabling programmed deformation from a 2D planar cell-laden structure to a well-defined 3D tubular shape, which facilitated the facile 3D endothelialization of small-diameter vascular grafts.
› Verified 9 days ago
| Entity Name | Rutgers Health Behavioral Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891956298 PECOS PAC ID: 2466346770 Enrollment ID: O20040419001021 |
News Archive
Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Recently, a research team led by Dr. DU Xuemin at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences created a new shape-morphing scaffold, enabling programmed deformation from a 2D planar cell-laden structure to a well-defined 3D tubular shape, which facilitated the facile 3D endothelialization of small-diameter vascular grafts.
› Verified 9 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Complex Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154379626 PECOS PAC ID: 0446272298 Enrollment ID: O20060109000000 |
News Archive
Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Recently, a research team led by Dr. DU Xuemin at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences created a new shape-morphing scaffold, enabling programmed deformation from a 2D planar cell-laden structure to a well-defined 3D tubular shape, which facilitated the facile 3D endothelialization of small-diameter vascular grafts.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ewaen Osamuyi Okao, MD, 661 Shrewsbury Ave, Shrewsbury, NJ 07702-4183 Ph: (732) 345-3400 | Ewaen Osamuyi Okao, MD, 13 N Hartford Ave, Atlanticare Behavioral Health, Atlantic City, NJ 08401-3512 Ph: (609) 348-1161 |
News Archive
Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Recently, a research team led by Dr. DU Xuemin at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences created a new shape-morphing scaffold, enabling programmed deformation from a 2D planar cell-laden structure to a well-defined 3D tubular shape, which facilitated the facile 3D endothelialization of small-diameter vascular grafts.
› Verified 9 days ago
Dr. Anup S Mani, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 13 N Hartford Ave, Atlantic City, NJ 08401 Phone: 609-348-1161 | |
Dr. Tina M Lusignolo, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 108 S Raleigh Ave, Atlantic City, NJ 08401 Phone: 617-480-3032 | |
Dr. David Martin Zeidwerg, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-345-4000 | |
Maria Teresa S Daclan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 13 N Hartford Ave, Atlantic City, NJ 08401 Phone: 609-348-1161 | |
Arturo A Gomez, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13 N Hartford Ave, Atlantic City, NJ 08401 Phone: 609-348-1161 | |
Mohammad Ashfaq, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12 N Providence Ave, Atlantic City, NJ 08401 Phone: 609-348-1161 |